Neil Kumar, Chief Executive Officer at BridgeBio Pharma, Inc. (BBIO), sold 128,088 shares at $73.16 ($9.5M) on 2025-12-04, disclosed to the SEC on 2025-12-08.
Scheduled sale ($9.5M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $73.16 | 2,100 | $154K | 1.6% |
| 2 | $74.42 | 12,192 | $907K | 9.6% |
| 3 | $74.42 | 12,192 | $907K | 9.6% |
| 4 | $74.42 | 12,200 | $908K | 9.6% |
| 5 | $74.80 | 5,708 | $427K | 4.5% |
| 6 | $74.80 | 5,700 |
| $426K |
| 4.5% |
| 7 | $74.80 | 5,708 | $427K | 4.5% |
| 8 | $73.04 | 12,288 | $898K | 9.5% |
| 9 | $73.04 | 12,288 | $898K | 9.5% |
| 10 | $73.05 | 12,517 | $914K | 9.7% |
| 11 | $73.05 | 12,517 | $914K | 9.7% |
| 12 | $73.75 | 7,712 | $569K | 6.0% |
| 13 | $73.76 | 7,483 | $552K | 5.8% |
| 14 | $73.76 | 7,483 | $552K | 5.8% |
| Total | $73.80 avg | 128,088 | $9.5M | 100% |
| Filing → |
| BBIO | SELL | 2026-06-08 | $4.6M | — | Filing → |
| BBIO | SELL | 2026-05-26 | $1.8M | — | Filing → |
| BBIO | SELL | 2026-05-11 | $5.3M | — | Filing → |